Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

Returns on capital

Rani Therapeutics Holdings, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-89.9%

avg -274.2%

ROIC

-80.6%

avg -89.1%

ROA

-50.6%

avg -51.8%

Analysis

ROA is currently the strongest return metric at -50.6% versus its period average of -51.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Nicholas Maestas

Chief Financial OfficerUSD 791.41K462.00M3.06%

Kate McKinley

Chief Business OfficerUSD 742.37K48805.50K1.23%

Talat Imran

Chief Executive Officer & DirectorUSD 549.93K44461.81K0.71%

Mir Hashim

Chief Scientific OfficerUSD 416K66325.00K0.50%

Mir A. Imran

Executive ChairmanUSD 30K702.12M3.24%

Alireza Javadi

Chief Technical Officer—429.07K0.01%

Jesper Hoeiland

Head of Strategy—66——

Bella Vazquez

Senior Vice President of People & Administrative Services————

Arvinder Dhalla

Vice President of Clinical Development————

Compensation is shown in the reported currency; data updated Oct 3, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 27, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$50,033.00

Sells

1

$301.08

Net Transaction Value

+$49,731.92

Net buying

Most Active

IMRAN MIR A

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 21, 26

IMRAN MIR A

Direct

Buy$24.8K
Jul 17, 26

Imran Talat

Direct

Buy$25.2K
Mar 27, 26

Javadi Alireza

Direct

Sell$301.1

Summary

Insiders reported 2 buys worth $50,033.00 and 1 sells worth $301.08 over the last 12 months. That adds up to net buying of $49,731.92. IMRAN MIR A was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+94.7% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Forward estimates point to Revenue at +94.7% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Rani Therapeutics Holdings, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about RANI's management, answered from reported figures.

Who manages RANI?

Rani Therapeutics Holdings, Inc. (RANI) lists 9 active executives. The top listed executive is Mir Hashim, Chief Scientific Officer.

Are RANI insiders buying or selling?

Recent insider activity shows net selling of $4.54M.